National Comprehensive Cancer Network

NCCN Research & Business Resources

Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions

Select a cancer below for additional information on active trials.

Adenoid Cystic Carcinoma

Alan L. Ho, MD, PhD

Memorial Sloan-Kettering Cancer Center

A Phase II Study of Axitinib (AG-013736) in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

 

Brain Cancer

Marc Chamberlain, MD

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington

Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastomas)

 

Breast Cancer

Sarat Chandarlapaty, MD, PhD	Memorial Sloan-Kettering Cancer Center	A Phase I/II Trial of Temsirolimus plus Neratinib for Patients with Metastatic HER2-Amplified or Triple- Negative Breast Cancer
Jasgit Sachdev, MD	University of Tennessee Cancer Institute	Neoadjuvant Weekly nab-Paclitaxel (Abraxane®) Plus Carboplatin followed by Doxorubicin Plus Cyclophosphamide with Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer
Jennifer Specht, MD	University of Washington/Seattle Cancer Care Alliance	DCE-MRI and FDG-PET with Kinetic Analysis to Monitor Breast Cancer Response to Neoadjuvant Sunitinib and Metronomic Chemotherapy

 

Gastrointestinal Cancer

R. Kate Kelley, MD	UCSF Helen Diller Family Comprehensive Cancer Center	A Phase I/II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Nikhil I. Khushalani, MD	Roswell Park Cancer Institute	Pralatrexate in Combination with Oxaliplatin in Advanced Esophago-Gastric Cancer: A Phase II Trial with Predictive Molecular Correlates
Jeffrey S. Rose, MD	The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute	Phase II Study of Pralatrexate and Docetaxel in Patients with Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-Based Therapy

 

Gynecologic Cancer

Susana Campos, MS, MD, MPH	Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center	A Phase I/IB Study of AZD2171 (Cediranib) and Temsirolimus in Patients with Advanced Gynecological Malignancies
Marcela G. del Carmen, MD, MPH	Massachusetts General Hospital Cancer Center	Phase I/II Study of Carboplatin and Pralatrexate in Patients with Recurrent Platinum Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

 

Head and Neck Cancers

Jeffrey Allen, MD	University of Tennessee Cancer Institute	A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Matthew Fury, MD, PhD	Memorial Sloan-Kettering Cancer Center	A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Matthew Fury, MD, PhD	Memorial Sloan-Kettering Cancer Center	Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane®) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients with Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Alan L. Ho, MD, PhD	Memorial Sloan-Kettering Cancer Center	A Multi-Institution Phase II Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Theodoros N. Teknos, MD	The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute	A Phase I Trial of Vorinostat in the Treatment of Advanced Oropharyngeal Carcinoma of the Head and Neck” Award
Francis P. Worden, MD	University of Michigan Comprehensive Cancer Center	Phase II Trial Evaluating Axitinib in Patients with Unresetable, Recurrent or Metastatic Head and Neck Cancer

 

Hematologic Malignancies

Seema Bhat, MD	Roswell Park Cancer Institute	A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia
Jennifer Brown, MD, PhD	Dana-Farber Cancer Institute	Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL
Alessandra Ferrajoli, MD	The University of Texas MD Anderson Cancer Center	Phase II Study of Ofatumumab as front-line treatment in elderly, unfit patients with Chronic Lymphocytic Leukemia (CLL)
Francisco Hernandez, MD	Roswell Park Cancer Institute	Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma (MCL)
Michaela Liedtke, MD	Stanford Cancer Institute	A Phase I Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
Shuo Ma, MD, PhD	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Correlative Studies in Conjunction with A Phase II Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

 

Kidney Cancer

John Hoffman, MD	Huntsman Cancer Institute at the University of Utah	Sutent® (Sunitinib Malate) for Metastatic Renal Cell Cancer with Imaging Biomarker Assessments for the Early Prediction of Tumor Response
Andrew Quon, MD	Stanford Cancer Institute	Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

 

Lung Cancer

Griffith Harsh, MD	Stanford Cancer Institute	Phase I Trial of Vorinostat Concurrent with Stereotactic Radiotherapy in Treatment of Brain Metastases from Non-Small Cell Lung Cancer
Ranee Mehra, MD	Fox Chase Cancer Center	Phase I Study of the HDAC Inhibitor Vorinostat with Chemotherapy and Radiation Therapy for the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Gregory Otterson, MD	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute	Phase II Trial of Abraxane plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding from VEGF Directed Therapies
Francisco Robert, MD	University of Alabama at Birmingham Comprehensive Cancer Center	Phase I/IIa Study of the Novel Combination of Bendamustine with Irinotecan Followed by Etoposide/ Carboplatin in Chemonaive Patients with Extensive Stage Small Cell Lung Cancer

 

Melanoma

Nikhil I. Khushalani, MD

Roswell Park Cancer Institute

Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma

 

Neuroendocrine/Carcinoid Tumors

Jonathan Strosberg, MD	H. Lee Moffitt Cancer Center & Research Institute	A Phase II Study of Axitinib in Advanced Carcinoid Tumors
Herbert I. Hurwitz, MD	Duke Cancer Institute	Phase I Dose Escalation of Pazopanib Plus TH302 in Advanced Solid Tumors
Halla Nimeiri, MD	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET)

 

Pancreatic Adenocarcinoma

Emily Chan, MD, PhD

Vanderbilt-Ingram Cancer Center

Phase I Trial of Chemoradiation with Capecitabine and Vorinostat in Pancreatic Cancer

 

Prostate Cancer

Andrew Armstrong, MD, ScM	Duke Cancer Institute	Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology in Men with Castration Resistant Metastatic Prostate Cancer
Sandhya Srinivas, MD	Stanford Cancer Institute	Using Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients with Castration-Resistant Prostate Cancer

 

Sarcomas

Warren Chow, MD	City of Hope Comprehensive Cancer Center	Randomized, Phase II Trial of AZD6244 alone and AZD6244 plus Temsirolimus for Soft Tissue Sarcomas
David Loeb, MD, PhD	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase I/II Trial of Torisel® and Liposomal Doxorubicin in Patients with Advanced Soft Tissue and Bone Sarcomas
Margaret von Mehren, MD	Fox Chase Cancer Center	Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma
William D. Tap, MD	Memorial Sloan-Kettering Cancer Center	A Phase IB/II Study of Gemcitabine and Docetaxel in Combination with Pazopanib (gem/doce/pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

 

Solid Tumors

Michaela Cristea, MD	City of Hope Comprehensive Cancer Center	Phase I Trial of Intraperitoneal nab-Paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity
Ira Dunkel, MD	Memorial Sloan-Kettering Cancer Center	Phase I Study of Perifosine with Temsirolimus for Recurrent Pediatric Solid Tumors
John Grecula, MD	The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute	Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients with 1-3 Brain Metastases from Solid Malignancies
Jean L. Grem, MD	UNMC Eppley Cancer Center at The Nebraska Medical Center	A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-Hour Infusion of 5-Fluorouracil Given Every Other Week in Adult Patients with Solid Tumors
Razelle Kurzrock, MD	The University of Texas MD Anderson Cancer Center	Phase I Trial of Hepatic Arterial Infusion of Abraxane with a Pharmacokinetic Study in Advanced Solid Cancer Patients with Predominant Hepatic Metastases
Edward Pan, MD	H. Lee Moffitt Cancer Center & Research Institute	Phase I Study of Bendamustine with Concurrent Whole Brain Radiation Therapy in Patients with Brain Metastases from Solid Tumors
Apostolia-Maria Tsimberidou, MD, PhD	The University of Texas MD Anderson Cancer Center	A Phase I Study of Bendamustine and Bevacizumab for Patients with Advanced Cancers
Jennifer J. Wheler, MD	The University of Texas MD Anderson Cancer Center	Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy

 

Thyroid Cancer

Nilofer S. Azad, MD	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	A Phase I Study Determining the Safety and Tolerability of Combination Therapy with Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK 1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched with Patients with Advanced Differentiated Thyroid Cancer
Laura QM Chow, MD	University of Washington/Seattle Cancer Care Alliance	A Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake
Eric J. Sherman, MD	Memorial Sloan-Kettering Cancer Center	Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer